Private Advisor Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Private Advisor Group’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-583	Closed	-$234K	–	2299
2023 Q2	$234K	Buy	583 +61	+12%	+$24.8K	﹤0.01%	1776
2023 Q1	$250K	Buy	+522	New	+$244K	﹤0.01%	1672
2022 Q3	–	Sell	-1,266	Closed	-$627K	–	1938
2022 Q2	$627K	Buy	+1,266	New	+$659K	0.01%	1287
2022 Q1	–	Sell	-1,007	Closed	-$760K	–	2103
2021 Q4	$760K	Sell	1,007 -550	-35%	-$412K	0.01%	1250
2021 Q3	$1.16M	Buy	1,557 +721	+86%	+$540K	0.01%	1137
2021 Q2	$538K	Buy	+836	New	+$509K	﹤0.01%	1355
2020 Q3	–	Sell	-16	Closed	-$7K	–	1764
2020 Q2	$7K	Buy	+16	New	+$7.06K	﹤0.01%	3064
2019 Q2	–	Sell	-1,238	Closed	-$378K	–	1670
2019 Q1	$378K	Buy	+1,238	New	+$334K	0.01%	1079
2018 Q4	–	Sell	-946	Closed	-$296K	–	1375
2018 Q3	$296K	Buy	946 +71	+8%	+$22K	0.01%	1230
2018 Q2	$253K	Buy	+875	New	+$242K	﹤0.01%	1074
2018 Q1	–	Sell	-991	Closed	-$248K	–	1181
2017 Q4	$248K	Buy	+991	New	+$240K	0.01%	959

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Private Advisor Group's BIO Position: Q3 2023 in Review

Private Advisor Group sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2023, closing a stake of 583 shares — an estimated $234K sold.

Private Advisor Group first reported a position in BIO in Q4 2017 and held it in 11 quarters. The position peaked at $1.16M in Q3 2021. 468 funds tracked by Wall St. Rank hold BIO as of Q3 2023.

Private Advisor Group reported no remaining Bio-Rad Laboratories Class A position as of Q3 2023 after selling out during the quarter.
Private Advisor Group sold 583 Bio-Rad Laboratories Class A shares in Q3 2023, an estimated $234K.
Private Advisor Group first reported a position in Bio-Rad Laboratories Class A in Q4 2017 and held it in 11 quarters.
Private Advisor Group's Bio-Rad Laboratories Class A position peaked at $1.16M in Q3 2021.
468 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2023.

Based on Private Advisor Group's 13F filing for Q3 2023, filed 3 Nov 2023.